A Randomized, Adaptive, Open-Label Phase 2 Dose Range Study of Novel Regimens for the Treatment of Pulmonary Tuberculosis (RAD-TB).

 

Key Inclusion Criteria:

1. Patient with pulmonary tuberculosis identified up to 7 days prior to screening

2. No history of pulmonary TB in the last 5 years

3. No use of TB medication for more than 7 days prior to study entry (e.g., INH, RIF, LZD, PZA)

4. No extrapulmonary TBr

5. No use of MTB medication 90 days prior to study entry

6. No current or previous MTB-resistant infection

​

Status: Starting soon.